Mureidomycin A, a new inhibitor of bacterial peptidoglycan synthesis
Citations Over TimeTop 23% of 1991 papers
Abstract
Mureidomycin A (MRD), a novel peptidylnucleoside antibiotic with antipseudomonal activity, inhibited not only peptidoglycan synthesis but also lipid-intermediate formation from UDP-N-acetylmuramyl (MurNAc)-pentapeptide and UDP-N-acetylglucosamine in an in vitro peptidoglycan-synthesizing system, using ether-treated cells of Pseudomonas aeruginosa. Both types of inhibition by MRD disappeared when UDP-MurNAc-pentapeptide was preincubated with ether-treated cells. Moreover, MRD completely inhibited lipid-intermediate I (undecaprenyl-p-p-MurNAc-pentapeptide) formation at a concentration below the MIC. From these results, it was concluded that the real target of MRD's action was translocase, which catalyzes lipid-intermediate I formation from UDP-MurNAc-pentapeptide and a lipid carrier.
Related Papers
- → Lipid II: A central component in bacterial cell wall synthesis and a target for antibiotics(2008)119 cited
- → Substrate analogues to study cell-wall biosynthesis and its inhibition(2002)46 cited
- → Molecular Dynamics Studies of Lipid I and Lipid II in Various of Lipid Bilayer Environments(2015)
- → A Molecular Dynamics Simulation Study of Lipid-Linked Peptidoglycan Precursors in Lipid Bilayers(2014)
- → Choice of drugs to manage anthrax(2004)